GLYC:NSD-GlycoMimetics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 0.2961

Change

+0.01 (+5.15)%

Market Cap

USD 0.16B

Volume

1.32M

Analyst Target

USD 9.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-3.50 (-0.74%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

-20.57 (-1.97%)

USD 115.81B
MRNA Moderna Inc

-1.12 (-0.96%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+1.07 (+0.43%)

USD 31.32B
ARGX argenx NV ADR

-0.20 (-0.05%)

USD 25.94B
BNTX BioNTech SE

+1.10 (+1.40%)

USD 20.40B
GMAB Genmab AS

+0.25 (+1.00%)

USD 16.65B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 15.75B
BGNE BeiGene Ltd

+4.05 (+2.81%)

USD 15.73B
BMRN Biomarin Pharmaceutical Inc

-1.25 (-1.51%)

USD 15.63B

ETFs Containing GLYC

VVMX:XETRA VanEck Rare Earth and Str.. 6.63 % 0.00 %

+0.04 (+1.05%)

USD 0.09B
REMX VanEck Rare Earth/Strateg.. 5.33 % 0.59 %

+1.45 (+1.05%)

USD 0.28B
SETM Sprott Energy Transition .. 4.01 % 0.00 %

+0.77 (+1.05%)

USD 0.01B
MVW:AU VanEck Vectors Australian.. 1.50 % 0.00 %

N/A

USD 2.27B
ZSB USCF Sustainable Battery .. 1.25 % 0.00 %

+0.16 (+1.05%)

USD 1.49M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -87.45% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.45% 4% F 2% F
Trailing 12 Months  
Capital Gain -82.88% 13% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.88% 13% F 7% C-
Trailing 5 Years  
Capital Gain -97.49% 15% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.49% 15% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 2.91% 61% D- 53% F
Dividend Return 2.91% 61% D- 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.60% 35% F 20% F
Risk Adjusted Return 3.71% 60% D- 43% F
Market Capitalization 0.16B 21% F 17% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 3.99 38% 28%
Price / Cash Flow Ratio -0.52 22% 56%
Price/Free Cash Flow Ratio -2.87 63% 71%
Management Effectiveness  
Return on Equity -81.84% 47% 23%
Return on Invested Capital -96.57% 30% 13%
Return on Assets -47.82% 27% 10%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.